Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-4 Registration of securities issued in business combination transactions
- 3.1 EX-3.1
- 10.1 EX-10.1
- 10.2 EX-10.2
- 10.3 EX-10.3
- 10.4 EX-10.4
- 10.5 EX-10.5
- 10.6 EX-10.6
- 10.7 EX-10.7
- 10.8 EX-10.8
- 10.9 EX-10.9
- 10.10 EX-10.10
- 10.11 EX-10.11
- 10.12 EX-10.12
- 10.13 EX-10.13
- 10.14 EX-10.14
- 10.15 EX-10.15
- 10.16 EX-10.16
- 10.17 EX-10.17
- 23.3 EX-23.3
- 23.4 EX-23.4
- 23.5 EX-23.5
- 23.6 EX-23.6
- 99.1 EX-99.1
- 99.2 EX-99.2
Vidara Therapeutics International Public similar filings
Filing view
External links
Exhibit 23.6
Consent of Independent Auditors
We consent to the incorporation by reference in this registration statement on Form S-4 and related prospectus/proxy statement of our report dated January 16, 2014, with respect to the statement of assets acquired of the VIMOVO Product Line of AstraZeneca LP as of December 31, 2012, and the related statement of net revenues and direct expenses for the year then ended, which report appears in the Form8-K/A of Horizon Pharma, Inc. dated February 6, 2014.
/s/ KPMG LLP
Philadelphia, Pennsylvania
June 26, 2014